Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2005

Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle. 2005;4(9):1131-3.

Jungbluth AA, Ely S, Diliberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005;106(1):167-74.

Garcia-Cao I, Duran A, Collado M, Carrascosa MJ, Martín-Caballero J, Flores JM, et al. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep. 2005;6(6):577-83.

Ross P, Magro CM. Clonal light chain restricted primary intrapulmonary nodular amyloidosis. Ann Thorac Surg. 2005;80(1):344-7.

Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005;102(51):18443-8.

Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol. 2005;18(3):324-30.

Hoang CD, Boettcher AK, Jessurun J, Pambuccian SE, Bullard KM. An unusual rectosigmoid mass: endometrioid adenocarcinoma arising in colonic endometriosis: case report and literature review. Am Surg. 2005;71(8):694-7.

Li Z, Paik J-, Paik J-, Wang Z, Hla T, Wu D. Role of guanine nucleotide exchange factor P-Rex-2b in sphingosine 1-phosphate-induced Rac1 activation and cell migration in endothelial cells. Prostaglandins Other Lipid Mediat. 2005;76(1-4):95-104.

Restelli M, Grinstein S, Gattuso P, M Preciado V, Brunzini MA, Zarate J, et al. Immunolocalization of the Epstein-Barr nuclear antigen-1 in conjunctival squamous carcinomas and dysplasias. Hum Pathol. 2005;36(4):325-9.

Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23(24):5696-704.